MX359366B - Composición farmacéutica de liberación sostenida que comprene un agente antibacterial. - Google Patents
Composición farmacéutica de liberación sostenida que comprene un agente antibacterial.Info
- Publication number
- MX359366B MX359366B MX2013004711A MX2013004711A MX359366B MX 359366 B MX359366 B MX 359366B MX 2013004711 A MX2013004711 A MX 2013004711A MX 2013004711 A MX2013004711 A MX 2013004711A MX 359366 B MX359366 B MX 359366B
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical compositions
- carriers
- useful
- emulsifier
- further embodiments
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000969 carrier Substances 0.000 abstract 2
- 239000004599 antimicrobial Substances 0.000 abstract 1
- 238000004090 dissolution Methods 0.000 abstract 1
- 239000003995 emulsifying agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40883010P | 2010-11-01 | 2010-11-01 | |
| PCT/US2011/058743 WO2012061360A2 (en) | 2010-11-01 | 2011-11-01 | Pharmaceutical compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2013004711A MX2013004711A (es) | 2013-08-29 |
| MX359366B true MX359366B (es) | 2018-09-26 |
Family
ID=46025057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013004711A MX359366B (es) | 2010-11-01 | 2011-11-01 | Composición farmacéutica de liberación sostenida que comprene un agente antibacterial. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US9409896B2 (https=) |
| EP (1) | EP2635307B1 (https=) |
| JP (1) | JP5902188B2 (https=) |
| KR (1) | KR20140022773A (https=) |
| CN (1) | CN103379917B (https=) |
| AU (1) | AU2011323594C1 (https=) |
| BR (1) | BR112013010714A2 (https=) |
| CA (1) | CA2816077C (https=) |
| EA (1) | EA028054B1 (https=) |
| ES (1) | ES2824898T3 (https=) |
| HU (1) | HUE051133T2 (https=) |
| IL (1) | IL225952A0 (https=) |
| MX (1) | MX359366B (https=) |
| NZ (1) | NZ609964A (https=) |
| PH (1) | PH12013500882A1 (https=) |
| PT (1) | PT2635307T (https=) |
| SG (2) | SG10201508982TA (https=) |
| UA (1) | UA114469C2 (https=) |
| WO (1) | WO2012061360A2 (https=) |
| ZA (1) | ZA201303177B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201407724YA (en) | 2009-11-23 | 2014-12-30 | Cubist Pharm Inc | Daptomycin compositions and related methods |
| AU2011332031B2 (en) | 2010-11-24 | 2017-01-12 | Melinta Subsidiary Corp. | Pharmaceutical compositions |
| CN104364240B (zh) * | 2012-06-08 | 2017-02-22 | 四川贝力克生物技术有限责任公司 | 一种用于预防或治疗分支杆菌疾病的药物 |
| SG11201605580RA (en) | 2014-01-10 | 2016-10-28 | Anaptysbio Inc | Antibodies directed against interleukin-33 (il-33) |
| EP4058020A4 (en) * | 2019-12-26 | 2023-04-12 | Santa Farma Ilaç Sanayi A.S. | SOLID ORAL PHARMACEUTICAL GEMIFLOXACIN MESYLATE COMPOSITION WITH IMPROVED RELEASE PROFILE AND MECHANISM OF DISINTEGRATION |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2255663C (en) | 1996-05-24 | 2002-08-20 | Schering Corporation | Antifungal composition with enhanced bioavailability |
| CN1207895A (zh) | 1997-08-12 | 1999-02-17 | 陕西省西安制药厂 | 一种克拉霉素胶囊 |
| ATE232087T1 (de) * | 1997-10-27 | 2003-02-15 | Merck Patent Gmbh | Feste lösungen und dispersionen von eines schlecht wasserlöslichen wirkstoffes |
| GB2331458B (en) * | 1997-11-21 | 2002-07-31 | Gursharan Singh Moonga | Solubilising systems for difficult pharmaceutical actives for preparing concentrated stable solutions for encapsulation into soft gelatine |
| KR19990080453A (ko) | 1998-04-17 | 1999-11-05 | 성재갑 | 비가역성 hiv 프로테아제 억제제를 함유하는 약제학적 조성물 |
| US7374779B2 (en) | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
| US20030180352A1 (en) * | 1999-11-23 | 2003-09-25 | Patel Mahesh V. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US7527807B2 (en) * | 2000-06-21 | 2009-05-05 | Cubist Pharmaceuticals, Inc. | Compositions and methods for increasing the oral absorption of antimicrobials |
| US6696426B2 (en) * | 2000-08-22 | 2004-02-24 | Pharmacia Corporation | Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems |
| US20020119196A1 (en) | 2000-12-21 | 2002-08-29 | Narendra Parikh | Texture masked particles containing an active ingredient |
| US7217431B2 (en) * | 2001-07-06 | 2007-05-15 | Lifecycle Pharma A/S | Controlled agglomeration |
| US7842791B2 (en) * | 2002-12-19 | 2010-11-30 | Nancy Jean Britten | Dispersible pharmaceutical compositions |
| CN101429170B (zh) | 2003-06-03 | 2015-05-13 | 梅林塔医疗有限公司 | 联芳基杂环化合物的制备和用途 |
| JP5043428B2 (ja) | 2003-06-03 | 2012-10-10 | リブ−エックス ファーマシューティカルズ，インコーポレイテッド | ビアリール複素環式化合物ならびにその製造および使用方法 |
| CA2540984C (en) | 2003-10-10 | 2011-02-08 | Lifecycle Pharma A/S | A solid dosage form comprising a fibrate |
| KR100854211B1 (ko) | 2003-12-18 | 2008-08-26 | 동아제약주식회사 | 신규한 옥사졸리디논 유도체, 그의 제조방법 및 이를유효성분으로 하는 항생제용 약학 조성물 |
| KR20050104152A (ko) | 2004-04-28 | 2005-11-02 | 최승호 | 경구용 약물의 흡수를 증진하는 약제학적 조성물 |
| EP1877041A2 (en) | 2005-04-29 | 2008-01-16 | Cubist Pharmaceuticals, Inc. | Therapeutic compositions |
| DE602006019870D1 (de) * | 2005-06-08 | 2011-03-10 | Rib X Pharmaceuticals Inc | Verfahren zur synthese von triazolen |
| WO2007103687A2 (en) * | 2006-03-01 | 2007-09-13 | Tristrata, Inc. | Composition and method for topical treatment of tar-responsive dermatological disorders |
| WO2007103873A2 (en) * | 2006-03-06 | 2007-09-13 | Wyeth | Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol |
| JP2009531420A (ja) * | 2006-03-27 | 2009-09-03 | パナセア バイオテック リミテッド | 酸可溶性ポリマーおよびｐＨ依存性ポリマーを含む放出系に基づく徐放性医薬組成物 |
| WO2008085913A1 (en) | 2007-01-04 | 2008-07-17 | Rib-X Pharmaceuticals, Inc. | Methods for treating, preventing, or reducing the risk of opthalmic, otic, and nasal infections |
| US20090061009A1 (en) * | 2007-08-29 | 2009-03-05 | Joseph Schwarz | Composition and Method of Treatment of Bacterial Infections |
| WO2010046933A2 (en) * | 2008-10-22 | 2010-04-29 | Rubicon Research Private Limited | Pharmaceutical compositions of taste-masked linezolid |
-
2011
- 2011-11-01 EP EP11838664.8A patent/EP2635307B1/en active Active
- 2011-11-01 SG SG10201508982TA patent/SG10201508982TA/en unknown
- 2011-11-01 NZ NZ609964A patent/NZ609964A/en not_active IP Right Cessation
- 2011-11-01 US US13/882,698 patent/US9409896B2/en active Active
- 2011-11-01 ES ES11838664T patent/ES2824898T3/es active Active
- 2011-11-01 SG SG2013033865A patent/SG190117A1/en unknown
- 2011-11-01 MX MX2013004711A patent/MX359366B/es active IP Right Grant
- 2011-11-01 CA CA2816077A patent/CA2816077C/en active Active
- 2011-11-01 PT PT118386648T patent/PT2635307T/pt unknown
- 2011-11-01 JP JP2013536921A patent/JP5902188B2/ja not_active Expired - Fee Related
- 2011-11-01 CN CN201180063510.8A patent/CN103379917B/zh not_active Expired - Fee Related
- 2011-11-01 BR BR112013010714A patent/BR112013010714A2/pt not_active IP Right Cessation
- 2011-11-01 KR KR1020137013955A patent/KR20140022773A/ko not_active Abandoned
- 2011-11-01 HU HUE11838664A patent/HUE051133T2/hu unknown
- 2011-11-01 WO PCT/US2011/058743 patent/WO2012061360A2/en not_active Ceased
- 2011-11-01 EA EA201390646A patent/EA028054B1/ru not_active IP Right Cessation
- 2011-11-01 UA UAA201306779A patent/UA114469C2/uk unknown
- 2011-11-01 PH PH1/2013/500882A patent/PH12013500882A1/en unknown
- 2011-11-01 AU AU2011323594A patent/AU2011323594C1/en not_active Ceased
-
2013
- 2013-04-25 IL IL225952A patent/IL225952A0/en unknown
- 2013-04-30 ZA ZA2013/03177A patent/ZA201303177B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201303177B (en) | 2018-12-19 |
| CN103379917B (zh) | 2016-10-12 |
| JP2013542226A (ja) | 2013-11-21 |
| EA028054B1 (ru) | 2017-10-31 |
| CN103379917A (zh) | 2013-10-30 |
| PT2635307T (pt) | 2020-11-03 |
| UA114469C2 (uk) | 2017-06-26 |
| EP2635307A4 (en) | 2014-11-05 |
| CA2816077A1 (en) | 2012-05-10 |
| AU2011323594B2 (en) | 2016-12-22 |
| CA2816077C (en) | 2021-08-10 |
| US9409896B2 (en) | 2016-08-09 |
| NZ609964A (en) | 2015-08-28 |
| KR20140022773A (ko) | 2014-02-25 |
| SG10201508982TA (en) | 2015-12-30 |
| IL225952A0 (en) | 2013-07-31 |
| MX2013004711A (es) | 2013-08-29 |
| US20140094463A1 (en) | 2014-04-03 |
| BR112013010714A2 (pt) | 2024-01-16 |
| AU2011323594A1 (en) | 2013-05-23 |
| AU2011323594C1 (en) | 2017-06-01 |
| HUE051133T2 (hu) | 2021-03-01 |
| WO2012061360A3 (en) | 2012-07-12 |
| JP5902188B2 (ja) | 2016-04-13 |
| EP2635307A2 (en) | 2013-09-11 |
| WO2012061360A2 (en) | 2012-05-10 |
| ES2824898T3 (es) | 2021-05-13 |
| EA201390646A1 (ru) | 2014-01-30 |
| PH12013500882A1 (en) | 2020-10-19 |
| SG190117A1 (en) | 2013-06-28 |
| EP2635307B1 (en) | 2020-07-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL279304A (en) | History of cytotoxic benzodiazepines, preparations containing them and their uses | |
| IL273838A (en) | Peptide and oligonucleotide conjugates, preparations containing them and their uses | |
| SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
| PL3111926T3 (pl) | Kompozycje, sposoby i układy do dostarczania dwóch lub większej liczby środków czynnych do układu oddechowego | |
| EA033311B1 (ru) | Производные бензоксаборола в качестве антибактериальных средств | |
| MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
| IL233154A (en) | Compounds, pharmaceuticals containing them and their uses | |
| MX2013002422A (es) | Sales de lorcaserina con acidos opticamente activos. | |
| MY166518A (en) | Nanocapsules containing microemulsions | |
| PL2132294T3 (pl) | Układ nośników substancji czynnych | |
| MX353024B (es) | Compuestos de fenil carbamato para uso en la prevencion o tratamiento de epilepsia. | |
| WO2013173789A3 (en) | Antisense oligonucleotide compositions | |
| MX2013009252A (es) | Composiciones y procesos relacionados con los mismos plaguicidas. | |
| PH12015501096A1 (en) | Composition for immediate and extended release | |
| TW201144301A (en) | Processes for preparing linezolid | |
| MX359288B (es) | Forma iv del clorhidrato de ivabradina. | |
| MX2012013855A (es) | Compuestos de oligobenzamida y su uso. | |
| IN2012DN02793A (https=) | ||
| MX364934B (es) | Agente para prevenir y/o tratar dolor neuropático periférico causado por fármaco contra el cáncer. | |
| PH12013500882A1 (en) | Pharmaceutical compositions | |
| MY165088A (en) | Pharmaceutical compositions comprising alisporivir | |
| MX338646B (es) | Sistema de suministro de fragancia de larga duracion. | |
| TR200909785A1 (tr) | Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar. | |
| MY161769A (en) | Pharmaceutical composition for treating hcv infections | |
| MX2009008991A (es) | Solucion solida amorfa que contiene un derivado de pirazol-3-carboxamida en forma amorfa y excipientes estabilizadores. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC | Change of company name or juridical status |
Owner name: ABBVIE INC.* |
|
| FG | Grant or registration | ||
| PD | Change of proprietorship |
Owner name: MELINTA SUBSIDIARY CORP. |